Molecular genetics and cellular events of K-Ras-driven tumorigenesis

GG Jinesh1,5, V Sambandam2,5, S Vijayaraghavan3,5, K Balaji3,5 and S Mukherjee4,5

Cellular transformation and the accumulation of genomic instability are the two key events required for tumorigenesis. K-Ras (Kirsten-rat sarcoma viral oncogene homolog) is a prominent oncogene that has been proven to drive tumorigenesis. K-Ras also modulates numerous genetic regulatory mechanisms and forms a large tumorigenesis network. In this review, we track the genetic aspects of K-Ras signaling networks and assemble the sequence of cellular events that constitute the tumorigenesis process, such as regulation of K-Ras expression (which is influenced by miRNA, small nucleolar RNA and lncRNA), activation of K-Ras (mutations), generation of reactive oxygen species (ROS), induction of DNA damage and apoptosis, induction of DNA damage repair pathways and ROS detoxification systems, cellular transformation after apoptosis by the blebbishield emergency program and the accumulation of genomic/chromosomal instability that leads to tumorigenesis.

Oncogene (2018) 37, 839–846; doi:10.1038/onc.2017.377; published online 23 October 2017

INTRODUCTION
Cancer remains a difficult disease to cure and the most common cause of disease-associated mortality. An incomplete understanding of the tumorigenesis process and the generation of heterogeneity within tumors renders therapeutic measures ineffective against cancer. Accumulating evidences point to the fact that the clones that develop resistance to therapy are cancer stem cells1 and often have genetic alterations in K-Ras.2 One major reason for heterogeneity/clonal difference is genomic instability, which generates cancer cells with structural or numeric chromosomal alterations that result in alterations to critical genes such as K-Ras3 that govern cell survival and immune evasion. In this review, we track the genetic aspects and sequence of cellular events that constitute the K-Ras-driven tumorigenesis process as a model for oncogene-driven tumorigenesis, with special focus on the role of cellular transformation and genomic instability and how RNA interference of K-Ras influences tumorigenesis.

K-RAS: GENETIC REGULATION OF EXPRESSION AND ACTIVATION
Ras oncogenes (HRAS, KRAS and NRAS) were discovered from viruses and were found to have transforming (sphere/focus-forming/anchorage-independent growth/clinogenic growth) properties.4 KRAS encodes a 21 kDa protein product and is a powerful member of the Ras oncogene family. KRAS has two alternatively spliced mRNA variants, namely, KRAS4A and KRAS4B.5 Human cells harbor the KRAS gene at chromosomal band 12p12.1.5

Once the KRAS gene is transcribed, the mRNA is either subjected to translation or RNA interference-mediated degradation (Figure 1 and Table 1). Let-7 micro-RNA (miR/miRNA) targets K-Ras mRNA for degradation through LCS (Let-7 complementary sites) within the K-Ras mRNA.6,7 Interestingly, Chin et al.8 used clinical specimens to identify that an LCS variant allele with a mutation in the miRNA-binding region was associated with K-Ras overexpression. H19 long non-coding RNA (IncRNA) blocks K-Ras mRNA degradation by antagonizing Let-7 miRNAs.9 Moreover, miR-16 directly targets the 3′-UTR of KRAS mRNA to block K-Ras expression10 (Figure 1). The extent to which miRNAs cross react with mRNAs of other ras oncogenes is not well understood. However, miRNA-18a was found to specifically target K-Ras miRNA without targeting transcripts of N-Ras or H-Ras11 (Figure 1). Furthermore, miRNA-622,12 miR-1/hsa-miR-1,13 miR-217,14 miR-143/145 (discussed below) and small nucleolar RNAs (discussed below) are also capable of targeting K-Ras expression (Figure 1).

Simply expressing K-Ras is not sufficient for tumorigenesis because when K-Ras was expressed under its own endogenous promoter with a conditional interferon inducible switch, it could only induce transformation and not acute myeloid leukemia.15 Thus, the genetic aspects of KRAS promoter regulation is not discussed in detail here. Genomic instability in combination with cellular transformation was suggested to enable K-Ras-driven tumorigenesis.15 This combination of cellular transformation and genomic instability also holds true for human papillomavirus-induced tumorigenesis.16

The expression of KRAS alone did not drive tumorigenesis because it did not account for the activation of K-Ras. When K-Ras is bound to guanosine diphosphate, it is in its inactive form, and when this guanosine diphosphate is replaced with guanosine triphosphate, K-Ras becomes activated.17 Activated cell surface receptors (usually receptor tyrosine kinases/RTKs) activate K-Ras. RTKs and Ras signaling collaborate to develop specific sub-types of cancer and thus are important for cancer therapy.17 Apart from...
proteins and activation. K-Ras also becomes constitutively activated by mutations in critical codons. High-frequency mutations (in clinical specimens), such as G12A, G12C, G12D, G12S, G12V, G13C and G13D, in addition to many other low-frequency mutations, are known to activate K-Ras.2–23 (Figure 1 and Table 1). These mutations interfere with guanosine triphosphate hydrolysis to make K-Ras constitutively active.24,25 However, this concept was recently questioned because the binding of guanosine triphosphate to mutant K-Ras may vary depending on the type of mutation.26 The K-RasG13D mutation directs ZNF304-DNMT1-mediated repression of tumor suppressor genes through promoter methylation.27 K-Ras mutations are frequently observed in cancers of the pancreas (57%), large intestine (33%), biliary tract (31%), small intestine (20%), lung (17%), endometrium (14%), ovary (14%), prostate (8%), cervix (7%), stomach (6%), urinary tract (5%), liver (5%), hematopoietic cells (5%) and other organs (≤5%).28 However, this could be an underestimation of the actual K-Ras activation status in cancer because these percentages only account for the mutant KRAS and not receptor-activated wild-type K-Ras. Mutations enable the oncogenic characteristics of both splice variants of KRAS (KRAS4A and KRAS4B).29 Wild-type K-Ras activation modules are protein-based modifications and will not be discussed in detail here. For more details on this and on small molecule inhibition of K-Ras, please see the latest excellent review.30

Epidermal growth factor receptor (EGFR), one of the prominent candidates implicated in cellular transformation, is tightly linked to K-Ras-induced pancreatic tumorigenesis.31 In addition, VEGFR2/KDR expression and PDGFRA expression were found to correlate with K-Ras activation.

### Table 1. Genetic and cellular events that regulate K-Ras-driven tumorigenesis

| Major event            | Negative regulation                                                                 | Positive regulation                                                                                     |
|------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| K-Ras expression       | miRNAs (Let-7a, miR-18a, miR-217, miR-622, miR-16-1, hsa-miR-1, miR-143/145), miR-30a and snoRNAs (SNORD50A, SNORD50B). | Incr-H19-mediated inhibition of miRNA Let-7a.                                                            |
| K-Ras activation       | DNA repair pathways that reverse K-Ras codon mutations.                               | Codon mutations (G12V, G12C, G12S, G12A, G12D, G13C and G13D), RTKs, smoking and ROS.                   |
| K-Ras-regulated non-coding RNAs | Potential miRNA target (miR-1298).                                                   | miR-26a), lncRNA ANRIL, FAK, ERK-1/2, glycolytic switch, and membrane fusion.                            |
| ROS generation         | Smac mimetics + TNF-α combination, BI-D1870, NAC, glutathione, NQO1 and Nrf-2.       | K-Ras interaction with p47phox, PKCs (PKC-ζ), and Ser-181-phosphorylation of K-Ras.                     |
| Apoptosis induction    | Antioxidant system (Nrf-2, SLC7A5, HMOX-1, NQO1), IRES translation                   | Lack of ATP after glycolytic shut down.                                                                 |
| Secondary necrosis     | BAD-Ser-112 phosphorylation by p70S6K and Pim-1 to boost glycolysis to generate ATP. | VEGF-A, VEGFR2, cell fusion, lactic acid, IRES translation and p70S6K.                                  |
| Blebbishield formation | Dynasore (Dynamin-dependent endocytosis inhibitor), and N-ethylmaleimide (NEM).      | Mutant p53 or loss of p53, cell fusion, mitotic defects (cytokinesis failure), DNA repair defects induced by K-Ras, blebbishield emergency program and chromosomal instability. |
| Blebbishield-mediated transformation | Neutalizing antibodies to VEGF-A and VEGFR2.                                        | K-Ras inhibitors, miRNA therapeutics, glycolysis inhibitors with apoptosis inducers, immunotherapeutics and other preclinical therapeutics. |
| Genomic instability    | Mitochondrial apoptosis through wild-type p53, p21, Bax/Bak, necrosis and senescence through pRb. |                                                                                                         |
| Tumorigenesis          | miRNAs (miR-216, miR-1298, miR-143/145, miR-16, Let-7a, miR-214, hsa-miR-1, miR-622, miR-217, miR-30a), induction of proper immunogenic apoptosis (wild-type p53, p21, cleaved Bax/Bak) and senescence (pRb) and snoRNAs (SNORD50A, SNORD50B). |                                                                                                         |
| Cancer therapy         | Blebbishield emergency program (inhibits cell death), glycolysis (inhibits secondary necrosis after apoptosis) and lack of functional wild-type p53. |                                                                                                         |
K-RAS: INDUCTION OF ROS, APOPTOSIS AND ROS DETOXIFICATION IN CELLULAR TRANSFORMATION

Once activated, K-Ras has a plethora of functions; however, the induction of reactive oxygen species (ROS) is the key step toward cellular transformation, genomic instability and tumorigenesis. K-Ras orchestrates ROS production by promoting the localization of NOX1 component p47phox to the plasma membrane and facilitates its interaction with protein kinase-C isoforms (PKC) to mediate cellular transformation36 (Figures 2 and 3 and Table 1). In addition, K-Ras activation is linked to an altruistic positive feedback loop between PKC-ζ, p47phox, and ROS wherein K-Ras facilitates p47phox to generate ROS, and ROS offers sustained activation status for PKC-ζ because PKC-ζ and p47phox are interacting partners36 (Figures 2 and 3). PKCs in turn phosphorylate both K-Ras isoforms (KRAS4A and KRAS4B) at Ser-181 to activate K-Ras,37,38 ROS production is, however, deleterious to cells as it can damage DNA through oxidative stress and induce apoptosis. Paradoxically, K-Ras can induce apoptosis, as well as promote tumorigenesis.39 Although these functions are contradictory in nature, ROS-induced apoptosis64,40 and K-Ras/VEGF/p19-VHL-directed survival functions (ROS neutralization by IGFBP3, SLC7A5 and SLC3A241) are utilized in sequence to complete cellular transformation by the blebbishield emergency program.42–44 Pim kinase isoforms are instrumental in protecting mitochondria from damage because loss of Pim kinase isoforms correlates with damage to mitochondria and the inhibition of cellular transformation.40 Inhibition of ROS by targeting PKC-ζ and p47phox abrogates cellular transformation.36 Thus, persistent altruistic feedback from ROS is needed to keep PKC-ζ active to regulate the expression of survival signals such as vascular endothelial growth factor (VEGF) and c-IAP2 through internal ribosome entry site (IRES) translation (Figure 3).

Persistent ROS generation can damage DNA and can activate p53 to promote full-blown apoptosis.45,46 To prevent p53 activation, K-Ras must either control the level of ROS generation or neutralize ROS. ROS detoxification is one way by which K-Ras and K-Ras122,23 overcome the deleterious effects of ROS. K-Ras regulates the expression of a panel of ROS detoxification mediators such as Nrf-2,47 NQO1,48 and HMox-1 to promote K-Ras-driven tumorigenesis49 (Table 1). Expression of the chief ROS detoxification mediator Nrf-2 in response to ROS is under the control of protein translation through p70S6K,50 which in turn is a downstream target of PKC-ζ (Figure 3). Thus, constitutive K-Ras activation leads to the constitutive activation of an altruistic feedback loop of ROS generation and sustained PKC activation, in which PKC-ζ drives the activation of p70S6K and regulates the expression of Nrf-2 to neutralize the toxic effects of ROS (Figure 3).

K-RAS AND BLEBBISHIELD-MEDIATED CELLULAR TRANSFORMATION AFTER APOPTOSIS

Soft-agar transformation assay has been the method of choice for decades to test the transforming ability of individual oncogenes. K-Ras knock-in was found to transform non-tumorigenic cells.52 Interestingly, soft-agar transformation is a long assay and takes days to weeks to reach an endpoint. Hence, the short-term events during cellular transformation were obscured for a long time. In the quest to understand cancer stem cells between low and high tumorigenic versions of bladder cancer cells, it was found that sphere formation (transformation) was preceded by apoptosis and a subsequent blebbishield emergency program, which rescues apoptotic cells and redirects them toward K-Ras-mediated cellular transformation.36,42,43,53 (Figure 3).

Smac mimetics in combination with death ligands such as tumor necrosis factor-α or tumor necrosis factor-related apoptosis-inducing ligand were found to effectively abrogate K-Ras activation, leading to massive cell death in cancer cells.44 Although FasL in combination with a Smac mimetic could induce apoptosis in cancer cells, a subset of apoptotic cells managed to survive after apoptosis and underwent cellular transformation (sphere formation) using the blebbishield emergency program.44 The blebbishield emergency program constructs blebbishields from apoptotic bodies using dnmamin-dependent endocytosis-driven serpentine filopodia, and the blebbishields in turn fuse to each other to undergo cellular transformation.36,42,43,53–55 The transformation phase of the blebbishield emergency program is driven by VEGF-activated VEGFR2 to activate K-Ras36,44 (Table 1). K-Ras signaling activates p70S6K (through ROS, PKC-ζ axis) to enhance IRES translation of VEGF to activate the VEGF autocrine loop44 (Figure 3). The blebbishields sustain VEGF secretion by maintaining p70S6K activation and thus continue IRES translation even during apoptosis.45,36 IRES translation also provides survival signals in the form of inhibitor of apoptotic proteins (IAPs)46 (Figure 3 and Table 1). DNA damage response is very important in the context of the blebbishield emergency program because DNA damage is a hallmark of apoptosis. The Nrf-2–ROS detoxification system has a direct role in activating DNA repair through homologous recombination57 (Figure 3).

K-Ras was found to be in an oligomerized state in parallel to BAD, Bax, Bak and p27 to boost glycolysis, so that the apoptotic cells were not subjected to secondary necrosis during the blebbishield emergency program.44 This could be one of the main reasons why cancer cells prefer glycolysis. Active K-Ras, p70S6K and Pim kinase-1 isoforms were found to have pivotal roles in the 'transformation'40 of cancer cells.
roles in blocking BAD-mediated apoptosis by maintaining the phosphorylation of BAD at its Serine-112 gatekeeper site. Compromising this phosphorylation using Smac mimetics plus tumor necrosis factor-α/tumor necrosis factor-related apoptosis inducing ligand leads to the abrogation of the transformation phase of blebbishield emergency program by promoting the depolarization of mitochondria and the induction of complete apoptosis (Table 1). Similarly, interfering with Ser-181 phosphorylation of K-Ras4A and K-Ras4B isoforms blocks tumorsogenesis and cellular transformation (foci formation), respectively. The blebbishield emergency program explains why K-Ras and BAD facilitate both apoptosis and cell survival, because apoptosis induction and subsequent survival are necessary for cellular transformation. In support of this notion, PARP inhibitors and the caspase-3 inhibitor z-DEVD-fmk were found to abrogate cellular transformation. Furthermore, soft-agar transformation and blebbishield emergency program-mediated cellular transformation are driven by an identical mechanism because a small molecule, CF3-DODA-Me, abrogates cellular transformation in soft-agar assays, as well as blebbishield-mediated sphere formation assay, by targeting drivers of the blebbishield emergency program.

**K-RAS: GENOMIC INSTABILITY, THE NEXT CRUCIAL STEP TOWARDS TUMORIGENESIS**

Cellular transformation that is induced by K-Ras is not enough to drive tumorigenesis. For efficient tumorigenesis, cells need to accumulate mutations or genomic instability. This is, in fact, demonstrated in the case of human papillomavirus-induced tumorsogenesis in which transformation and genomic instability together drive tumorigenesis. Thus, the generation of genomic instability is the next key step in K-Ras-driven tumorsogenesis. K-Ras activation causes early tumorsogenesis in a mouse model of lung cancer, suggesting the capability of K-Ras to induce both transformation and genomic instability. Genomic instability can occur within a specific location of the genome (for example, microsatellite instability) or at the chromosomal level as structural and/or numeric alterations (such as ploidy/aneuploidy, breakage-fusion-breakage/fusion-bridge cycle between chromosomes, or the translocation of chromosomal arms, resulting in fusion genes) (Figure 4). Even though cells have DNA repair mechanisms, defective DNA repair can lead to genomic instability.

**K-RAS: DNA REPAIR DEFECTS AND GENOMIC INSTABILITY**

Mismatch repair (MMR) is a small-scale DNA repair mechanism in cells. Defective MMR can lead to mutational hotspots/microsatellite instability and could be the cause of K-Ras activating mutations (Figure 4). EGFR is known to phosphorylate PCNA to inhibit MMR, therefore, it can increase mutation burden. In a pancreatic cancer mouse model, K-Ras upregulated EGFR expression, and genetic interference of EGFR eliminated K-Ras induced tumorsogenesis. Thus, K-Ras is associated with microsatellite instability in cancer, which might require other factors such as PCNA inhibition by EGFR to lead to defective MMR in K-Ras-driven tumorsogenesis.

DNA damage that is induced during apoptosis must be repaired by cells to override cell death and to undergo cellular transformation. To ensure protection from DNA damage, K-Ras-activated cells utilize various tactics, including the Nrf-2-dependent ROS detoxification system, which not only neutralizes ROS but also activates homologous recombination-mediated DNA repair (Figure 3). Telomere shortening-induced exposure of naked DNA ends at telomeric regions of chromosomes results in chromosome–chromosome fusion by the non-homologous end joining (NHEJ) mode of DNA repair to form breakage-fusion-bridge cycle (BFB cycle) type chromosomes. The classical NHEJ pathway contributes to genomic instability during mitosis if X-ray repair cross-complementing protein 4 (XRCC4) is not phosphorylated at the mitotic phase (M-phase). However, K-Ras targets an alternative XRCC4-independent NHEJ error-prone pathway that includes DNA ligase-3a, Poly (ADP-ribose) polymerase 1 and XRCC1 as components. Mutant K-Ras is known to upregulate the components of this error-prone alternative NHEJ pathway (DNA ligase-3a, Poly (ADP-ribose) polymerase 1 and XRCC1), and cells depend on this alternative NHEJ pathway during genotoxic stress. Thus, the MMR, homologous recombination and NHEJ modes of DNA repair can all be misused by K-Ras to generate genomic instability (Figure 4 and Table 1).

**K-RAS: CHROMOSOMAL INSTABILITY IN METABOLIC REPROGRAMMING, SURVIVAL AND STEMNESS**

Chromosomal instability is a large-scale genomic alteration with numerical or structural alterations in chromosomes. Deleting p53 in non-tumorigenic epithelial cells resulted in the generation of transformed phenotype and chromosomal instability. Rodrigues et al. also found that chromosomal instability is associated with cellular transformation. Thus, a transformation event can also generate chromosomal instability if p53 is compromised. KRAS mutation coupled to p53 loss can lead to tumorsogenesis. Recently, blebbishield emergency program is found to drive severe chromosomal instability by suppressing the expression of p53 during the transformation phase. In addition, EGFR, a K-Ras target, induces the expression of miR-26a in non-small cell lung cancer, and miR-26a promotes chromosomal instability and tumorsogenesis in breast cancer cells.

The accumulation of chromosome-8 has been predominantly correlated with genomic instability in multiple cancer types (Figure 4). Chromosome-8 harbors the Myc gene, one of the important targets of K-Ras (through the regulation of IRES translation). K-Ras and Myc are regulators of glycolysis to avert secondary necrosis of apoptotic cancer stem cells during blebbishield-mediated transformation. Thus, the control of K-Ras over metabolic reprogramming has a potential genetic basis, the chromosome-8 accumulation. Alternatively, mutant K-Ras copy number influences glucose metabolism and the TCA cycle to generate glutathione for ROS detoxification. Furthermore, the glycolysis metabolite lactic acid (lactate) offers strong survival advantages to cancer stem cells that undergo cellular transformation using the blebbishield emergency program by reducing the pH and potentially increasing the bioavailability of VEGF from the microenvironment. Further, targeting lactate dehydrogenase-A (an enzyme that converts pyruvate to lactate) has been shown to impede cellular transformation and tumorsogenesis. Thus, the blebbishield emergency program positively selects cells that are capable of
enhanced glycolysis, lactate production and survival after apoptosis. In addition, K-Ras has been linked to the accumulation of chromosomes-4, 10 and 12 in colorectal carcinomas. Among these, chromosome-4 harbors VEGFR2/KDR, c-Kit and PDGFRα in the same cytogenetic band (4q12) as a cluster where VEGFR2/KDR expression and PDGFRα expression were found to correlate with K-Ras codon 12 and 13 mutations in colorectal cancer. This is very important because VEGF/VEGFR2 signaling drives the blebbishield emergency program for cellular transformation and genomic instability or K-Ras. FAK, focal adhesion kinase; IncR, long non-coding RNA; miR, micro-RNA; ROS, reactive oxygen species.

Antagonizes Let-7 miRNA and increases K-Ras expression by reversing Let-7-mediated miRNA interference (Figure 5). In this context, H19 long non-coding RNA regulates cellular transformation and potentiates breast and lung tumorigenesis. An LC56 variant allele associated with K-Ras overexpression owing to a mutation in the miRNA-binding site increased the risk of lung cancer among smokers. Of note, smoking induces spontaneous mutations within the KRAS gene. In a spontaneous lung cancer mouse model driven by K-RasG12D and p53−/− genotype, miRNA-214 was found to be overexpressed. Impeding miR-214 blocked tumor growth to demonstrate the tumor-promoting role of miR-214 in a K-Ras mutant system (Figure 5). In breast cancer, miR-1 (hsa-miR-1) targets K-Ras to impede tumor growth and metastasis, thereby acting as a tumor suppressor. In addition, miRNA-622 targets K-Ras to inhibit transformation in vitro and tumorigenesis in vivo (Figure 5). Similarly, miR-217 targets K-Ras to inhibit cellular transformation and tumor growth in pancreatic ductal adenocarcinoma of mice (Figure 5). In glioblastoma multiforme, K-Ras expression was found to be necessary to maintain tumors in vivo, and loss of K-Ras led to apoptotic clearance of these cells. K-Ras was found to influence the expression of the long non-coding RNA ANRIL, which promotes lung cancer by inhibiting apoptosis (Figure 5).

K-Ras also exerts its oncogenic effects through ERK-1/297 and is negatively regulated by the small nucleolar RNA SNORD50A, and SNORD50B-mediated direct targeting of K-Ras and CRISPR/Cas9-mediated deletion of these small nucleolar RNAs enhance tumorigenesis. Taken together, these studies reiterate and confirm the fact that cellular transformation and genomic instability are two prominent features that are essential for K-Ras-driven tumorigenesis and highlight the dominance of genetic factors in K-Ras-driven tumorigenesis.

**SUMMARY AND FUTURE PERSPECTIVES**

K-Ras induces apoptosis through oxidative stress and then detoxifies ROS to induce DNA damage repair to regulate cellular transformation through the blebbishield emergency program and induces genomic instability to drive tumorigenesis. K-Ras could possibly mediate therapy resistance and relapse through the blebbishield emergency program because chemoresistant cancer clones were found to have a link to K-Ras. K-Ras in general is known to suppress the apoptotic program of death receptors and to redirect cells toward metastasis, which explains the importance of the blebbishield emergency program. In this context, inhibition of CDK4/6 gains importance as it could increase sensitivity to paclitaxel in K-Ras mutant cells or induce senescence and impede tumor growth with autophagy inhibitors.

A new avenue of miRNA therapeutics targeting K-Ras (based on tumor suppressor miRNAs Let-7a, miR-143, miR-145 and miR-200 family) is emerging at the preclinical level, highlighting the importance of K-Ras miRNA regulatory networks in cancer therapy. Although the expression of miR-26a in lung cancer suggests a link to K-Ras activation, the nature of this regulation remains unexplored (Figure 5). The introduction of miRNA-zippers, which lock two miRNAs together to inactivate both miRNAs and iExosomes (exosomes with siRNA or shRNA targeting KRASG12D miRNA), provides more choices for miRNA-based therapeutics. Thus, evaluating K-Ras in cancer relapse and expanding miRNA/NAI therapies against K-Ras-driven cancers are attractive and emerging avenues of research. Despite smoking being linked to mutational activation of K-Ras and driving tumorigenesis in the context of p53 mutations, an evaluation of oncogenic viruses in the induction of K-Ras mutations is much needed. This review will also serve as a model to explore the mechanism of other
oncogenes in various cancers for better understanding and better therapeutic development in the future.

CONFlict Of INTERest
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
The authors sincerely thank the University of Texas MD Anderson Cancer Center for literature access.

REFERENCES
1 Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275–284.
2 Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 2016; 375: 2255–2262.
3 Bartos JD, Matsui S, Willmott LJ, Sait SN et al. Genetic heterogeneity and instability in colorectal cancer: spectral karyotyping, glutathione transferase-M1 and ras. Mutat Res 2004; 566: 283–292.
4 Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM. Bladder cancer stem cells. Carcinogenesis 2012; 33: 304–317.
5 Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L et al. Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEF. Neuro-oncology 2013; 15: 1491–1501.
6 Cao L, Wang XF, Luo H, Li HL, Wang XR, Yan W et al. Conditional K-ras expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Carcinogenesis 2015; 36: 2835–2842.
7 Wang XZ, Luo H, Li HL, Cao L, Wang XF, Yan W et al. Ras oncoproteins: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761–774.
8 Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H et al. Human papillomavirus oncoproteins: pathways to transformation. J Clin Invest 2010; 120: 538–549.
9 Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z et al. H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMG2A-mediated EMT. Tumour Biol 2014; 35: 9163–9169.
10 You C, Liang H, Sun W, Li J, Liu Y, Fan Q et al. Deregression of the mir-16-KRAS axis promotes colorectal cancer. Sci Rep 2016; 6: 37459.
11 Schimanski CC, Zimmermann T, Schmidtmann I, Gockel I, Lang H, Galle PR et al. KRAS mutation status correlates with the expression of VEGF1, VEGF2 and PDGF-Ralpha in colorectal cancer. Int J Colorectal Dis 2010; 25: 181–186.
12 Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L et al. Novel PKC-zeta to p47 phox target motif. Blood 2013; 121: 2853–2862.
13 Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL, Kamat AM. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis. Cell Death Discov 2013; 2: 8540–8557.
14 Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK et al. Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations. Int J Environ Res Public Health 2012; 9: 2457–2467.
15 Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72: 2457–2467.
16 Ardito CM, Gruner BM, Takeuchi KK, Lubmeder-Martellato C, Teichmann N, Mazur PK et al. EGFR receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012; 22: 304–317.
17 Bartos JD, Stoler DL, Matsui S, Swede H, Willmott LJ, Sait SN et al. Small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov 2016; 15: 771–785.
18 Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72: 2457–2467.
19 Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Nat Rev Cancer 2002; 2: 456–469.
20 Jinesh GG, Taoka R, Zhang Q, Gorantla S, Kamat AM. Novel PKC-zeta to p47 phox interaction is necessary for transformation from blebbishields. Sci Rep 2016; 6: 23965.
21 Alvarez-Moya B, Lopez-Alcala C, Drosten M, Bachs O, Agell N. KRAS4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-ras activity and function. Oncogene 2010; 29: 5911–5922.
22 Barcelo C, Paco N, Morell M, Alvarez-Moya B, Bota-Rabassada N, Jaumot M et al. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth. Cancer Res 2014; 74: 1199–1209.
23 Jinesh GG, Taoka R, Zhang Q, Gorantla S, Kamat AM. Novel PKC-zeta to p47 phox interaction is necessary for transformation from blebbishields. Sci Rep 2016; 6: 23965.
Danial NN. BAD: undertaker by night, candyman by day.
Hahnel PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L
Feijoo P, Dominguez D, Tusell L, Genesca A. Telomere-dependent genomic
Jayakumar S, Pal D, Sandur SK. Nrf2 facilitates repair of radiation induced DNA
Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J. K-ras mutations in
Taoka RR, Jinesh GG, Xue W, Safe S, Kamat AM. CF3DODA-Me induces apoptosis,
Ortega J, Li JY, Lee S, Tong D, Gu L, Li GM. Phosphorylation of PCNA by EGFR
Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP et al. Knock-in
of mutant K-ras in nontumorigenic human epithelial cells as a new model for
studying K-ras mediated transformation. Cancer Res 2007; 67: 8460–8467.
Jinesh GG, Kamat AM. Blebbisheld emergency program: an apoptotic route to cellular transformation. Cell Death Differ 2012; 20: 4725–758.
Jinesh GG, Kamat AM. Blebbishelds and mitotic cells exhibit robust macro-
pinocytosis. Biofactor 2016; 43: 181–186.
Goodwin Jinesh G, Willis DL, Kamat AM. Bladder cancer stem cells: biological and therapeutic perspectives. Curr Stem Cell Res Ther 2014; 9: 89–101.
Jinesh GG, Mokkapati S, Zhu K, Morales EE. Pim kinase isoforms: devils defending cancer cells from therapeutic and immune attacks. Apoptosis 2016; 21: 1203–1213.
Jayakumar S, Pal D, Sandur SK. Nrf2 facilitates repair of radiation induced DNA damage through homologous recombination repair pathway in a ROS inde-
pendent manner in cancer cells. Mutat Res 2015; 779: 33–45.
Jinesh GG, Chunduru S, Kamat AM. Smac mimetic enhances the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and Fas. J Leukoc Biol 2012; 92: 233–244.
Jinesh GG, Kamat AM. Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncoimmunology 2012; 1: 1161–1162.
Danial NN. BAD: undertaker by night, candyman by day. Oncogene 2008; 27: 533–570.
Jinesh GG, Kamat AM. The blebbisheld emergency program overrides chromo-
osomal instability and phagocytosis checkpoints in cancer stem cells. Cancer Res 2017; doi: 10.1158/0008-5472.CAN-17-0522
Jinesh GG, Ganiraju M, Chinedu M, Keith AB, Kamat AM. Surface PD-L1, E-cad-
dermines microsatellite instability and phagocytosis checkpoints in cancer stem cells. Cancer Res 2009; 19: 5798–5807.
Milo GE, Kurian P, Kirsten E, Kun E. Inhibition of carcinogen-induced cellular transformation of human fibroblasts by drugs that interact with the poly(ADP-
ribose) polymerase system. Initial evidence for the development of transformation resistance. FEBS Lett 1985; 179: 332–336.
Taoka RR, Jinesh GG, Xue W, Safe S, Kamat AM. CF3DODA-Me induces apoptosis, degrades Sp1 and blocks the metastasis phase of the blebbisheld emer-
gency program. Apoptosis 2017; 22: 719–729.
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111–1116.
Ortega J, Li JY, Lee S, Tong D, Gu L, Li GM. Phosphorylation of PCNA by EGFR inhibits mismatch repair and promotes misincorporation during DNA synthesis. Proc Natl Acad Sci USA 2015; 112: 5667–5672.
Brentnall TA, Chen R, Lee JC, Kimmy MB, Bronner MP, Haggitt RC et al. Microsatellite instability and K-ras mutations associated with pancreatic ade-
nocarcinoma and pancreatitis. Cancer Res 1995; 55: 4624–4627.
Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001; 193: 193–199.
Lo AW, Sabatier L, Fouladi B, Pottier G, Ricoul M, Murnane JP. DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line. Neoplasia 2002; 4: 313–338.
Feijoo P, Dominguez D, Tussel L, Genesca A. Telomere-dependent genomic integrity: evolution of the fusion-bridge-breakage cycle concept. Curr Pharm Des 2014; 20: 6375–6385.
Hahnle PS, Enders B, Sasca D, Roos WP, Kaina B, Bullinger L et al. Targeting components of the alternative NHEJ pathway sensitzes KRAS mutant leukemic cells to chemotherapy. Blood 2014; 123: 2355–2366.
Weiss MB, Vitolo MI, Mosheni S, Rosen DM, Denmeade SR, Park BH et al. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene 2010; 29: 4715–4724.
Rodrigues CF, Urbano AM, Matoso E, Carreira I, Almeida A, Santos P et al. Human bronchial epithelial cells malignantly transformed by hexavalent chromium exhibit an aneuploid phenotype but no microsatellite instability. Mutat Res 2009; 670: 42–52.
Tang FH, Hsieh TH, Hsu CY, Lin HY, Long CY, Cheng KH et al. KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinomas in mice. Int J Cancer 2017; 140: 1860–1869.
100 Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. *Cancer Biol Ther* 2013; **14**: 597–605.

101 Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. *Nat Commun* 2017; **8**: 15916.

102 Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov* 2017; **16**: 203–222.

103 Meng L, Liu C, Lu J, Zhao Q, Deng S, Wang G et al. Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells. *Nat Commun* 2017; **8**: 13964.

104 Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. *Nature* 2017; **546**: 498–503.

105 Wang Y, Zhang Z, Lubet R, You M. Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. *Oncogene* 2005; **24**: 3042–3049.